Literature DB >> 9248816

Cultural and linguistic validation of questionnaires for use in international studies: the nine-item BPH-specific quality-of-life scale.

P Boyle1.   

Abstract

Questionnaires to evaluate symptoms and quality of life are being increasingly used in urology. It is, however, important that these questionnaires show equivalence when they are used in international, collaborative studies. Precise linguistic and cultural validation should greatly increase their compatibility in different population and cultural groups. Indeed, recent progress in the validation of symptom scores, such as the International Prostate Symptom Score (I-PSS), has helped international comparability in epidemiology and clinical trials. The management of benign prostatic hyperplasia (BPH) increasingly focuses on quality of life and the development of a successful BPH-specific quality-of-life questionnaire is an important advance in the study of BPH. The nine-item BPH-specific quality-of-life scale is currently undergoing linguistic and cultural validation and appears to be satisfactory for extensive use in different cultures.

Entities:  

Mesh:

Year:  1997        PMID: 9248816

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  BPH: How useful is a visual prostate symptom score for patients?

Authors:  Kamil Cam
Journal:  Nat Rev Urol       Date:  2011-09-20       Impact factor: 14.432

2.  Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery.

Authors:  A S Salinas-Sánchez; I Hernández-Millán; J G Lorenzo-Romero; M Segura-Martin; C Fernández-Olano; J A Virseda-Rodriguez
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

3.  Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia.

Authors:  Teddy Kajimotu; Kasonde Bowa
Journal:  PLoS One       Date:  2018-06-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.